Revenue grew 12% year-over-year to 228 million PLN, with EBITDA and net profit from continuing operations up 18%. Recurring revenue and radio-pharmaceuticals showed strong growth, and the group is expanding in robotic surgery and IT, with a major R&D spin-off and a 10.75 PLN/share dividend paid.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.